Calcitriol tablets with hybrid lipid-based solid dispersions with enhanced stability and content uniformity

Xiao, Yumei; Cui, Yingtong; Yuan, Ting; Huang, Zhengwei; Huang, Ying; Zhang, Xuejuan; Wang, Chen; Wang, Guanlin; Liang, Ruifeng; Liu, Chunxia; Pan, Xin; Wu, Chuanbin

doi:10.1080/10837450.2020.1760297

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is essential to closely monitor patients' blood Ca and Pi concentrations when using calcitriol. If blood Ca and Pi concentrations remain elevated, dosing adjustments or medication discontinuation may be necessary to prevent potential complications such as myocardial infarction due to vascular calcification [20].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of calcitriol in the treatment of patients with renal osteodystrophy

Jiang,

Tang,

Zhang

et al. 2024

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and prognosis of calcitriol in patients with renal osteodystrophy (ROD). Methods: 60 patients with ROD admitted to The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, China between June 2020 and June 2021 were randomly grouped into control (n = 30) and study groups (n = 30). Patients in control group received routine management study group was treated with routine management plus calcitriol. The treatment duration was six months. Serological markers (parathyroid hormone (PTH), calcium (Ca), and phosphorus (Pi)), renal function indices (blood creatinine (SCr), urea nitrogen (BUN), and alkaline phosphatase (ALP)), as well as patients’ skeletal conditions of the spine, pelvis, and extremities were investigated. Additionally, postoperative complications and clinical efficacy were also evaluated. Results: Study group showed significant improvement in serological markers compared to control group (p < 0.05). Also, study group had significantly reduced SCr, BUN, and ALP levels (p < 0.05) compared to control group. There was significantly reduced incidence of complications and better skeletal conditions in study group compared to control group (p < 0.05). Conclusion: Calcitriol effectively mitigates blood-bone mechanism dysfunction and reduces the occurrence of complications in patients with ROD. However, factors such as Scr, Hb, and blood pressure affect the clinical efficacy of calcitriol on renal bone disease by mechanisms that will be investigated in the future.

show abstract

Section: Discussionmentioning

confidence: 99%